NanoViricides Receives Approval for Phase II Ebola Trial in DRC

NanoViricides has received regulatory approval from ACOREP in the Democratic Republic of Congo to begin a Phase II clinical trial for NV-387 oral gummies. The antiviral treatment targets the Bundibugyo ebolavirus amid the largest ever ebola outbreak in DRC, which has recorded thousands of confirmed cases and high fatality rates.

As the Democratic Republic of Congo faces its largest ever ebola outbreak, clinical researchers are rushing to test alternative delivery systems for antiviral therapeutics. Traditional treatment protocols relying on infusions face severe logistical bottlenecks in resource-limited settings. The regulatory clearance of an oral formulation introduces a fundamentally different operational approach to managing viral containment in zones experiencing active displacement and infrastructure strain.

In Plain English: The Clinical Takeaway

• What is being tested? NV-387 oral gummies, an investigational broad-spectrum antiviral drug designed to target the Bundibugyo ebolavirus and other Ebola viruses.
• Why does an oral formulation matter? Unlike other treatments under consideration requiring infusions, an oral medication can be distributed and administered far more easily in remote or conflict-affected regions.
• What is the current trial phase? The drug is advancing into a Phase II clinical trial in the Democratic Republic of Congo, overseen by the local regulatory body ACOREP and managed by Om Sai Clinical Research Private Limited.

Epidemiological Pressures and the Scale of the Outbreak

The urgency behind evaluating NV-387 stems from severe epidemiological metrics reported by the World Health Organization. As of August 6, 2026, the ongoing outbreak of Ebola Virus Disease caused by the Bundibugyo ebolavirus has reached 4,141 confirmed cases and 1,889 confirmed deaths, yielding a crude fatality rate of 46%, according to the WHO. During the most recent complete reporting week, health authorities documented 567 new cases and 296 deaths, prompting reportage that the outbreak is “spreading like a wildfire”.

Compounding the clinical challenge is the geographic dispersion of the virus. Transmission is active in at least five provinces in the Democratic Republic of Congo. Public health surveillance indicates that over 80% of new cases are outside of known contact lists. This disconnect suggests the true scale of the epidemic may be at least two times or more larger than the reported confirmed cases. Furthermore, the virus has spread into displacement camps that host over 4.4 million displaced persons due to internal warfare. These environments feature poor drinking water, sanitation, and medical resources, creating high-risk pools for further fuel to this outbreak, according to the UN New Service.

Clinical Trial Design and Operational Logistics

To address these mounting pressures, NanoViricides retained Om Sai Clinical Research Private Limited as the CRO to execute the Phase II trial. The trial design prioritizes speed and operational feasibility in resource-constrained environments. The Principal Investigator submitted the regulatory application to ACOREP, which granted approval following preliminary preparation work by the clinical team to speed up the date to the first dosing of patients.

Company leadership emphasized the strategic advantage of deploying an oral candidate in an active epidemic. In a statement released by NanoViricides, Inc., President Anil R. Diwan, PhD, noted, “We believe NanoViricides is well positioned to provide an Oral Ebola treatment to save lives with our NV-387 Oral Gummies drug product that is already in place in DRC,” adding that “This unique and revolutionary oral broad-spectrum antiviral drug will now be tested in a clinical trial.”

This operational strategy contrasts with alternative approaches, such as the PARTNERS clinical trial, which will require over 1,000 patients to be treated and may not yield results for at least more than a year. Historical precedent from the West Africa outbreak demonstrated that large collaborative trials resulted in U.S. Food and Drug Administration approval of two antibody drugs specifically for EBOV Zaire. However, those therapeutics are not deemed to be useful in the current outbreak without further clinical trials.

Key Metrics of the Current Ebola Outbreak and Trial Parameters

Metric Category	Reported Data / Status	Source Reference
Confirmed Cases	4,141 cases (as of August 6, 2026)	World Health Organization (WHO)
Confirmed Deaths	1,889 deaths	World Health Organization (WHO)
Crude Fatality Rate	46%	World Health Organization (WHO)
Displaced Population at Risk	Over 4.4 million persons in camps	UN News Service
Clinical Trial Phase & Agent	Phase II Trial for NV-387 Oral Gummies	ACOREP / NanoViricides, Inc.

Contraindications & When to Consult a Doctor

Because NV-387 is an investigational drug currently entering Phase II evaluation, its complete safety profile, metabolic pathways, drug-drug interactions, and absolute contraindications remain subject to ongoing clinical validation. Patients presenting with acute hemorrhagic symptoms, unexplained fevers, or epidemiological links to confirmed Ebola cases must not seek out investigational agents outside of formal, regulated clinical trial protocols. Standard of care in an active EVD epidemic requires immediate isolation, supportive care, and authorized therapeutic administration within specialized treatment centers coordinated by the World Health Organization, Médecins Sans Frontières, and local ministries of health. Self-treatment or reliance on unverified compounds poses severe risks of clinical deterioration and accelerates community transmission.

Photo: biospace.com

Outlook for Broad-Spectrum Antiviral Development

The initiation of this Phase II trial marks a critical test for antiviral technology designed to prevent viral entry and replication across multiple viral strains. If clinical data corroborate preclinical expectations, an orally bioavailable therapeutic could fundamentally reshape outbreak management paradigms. By eliminating cold-chain storage and intravenous administration requirements, public health agencies could deploy treatments closer to the point of initial infection, potentially cutting transmission chains before they reach densely populated displacement settlements.

References:

• World Health Organization (WHO) – Disease Outbreak News on Ebola Virus Disease, Democratic Republic of Congo.
• U.S. Food and Drug Administration (FDA) – Approved Treatments for Ebola Virus Disease.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult qualified public health authorities or attending medical professionals for guidance regarding infectious disease protocols.